Skip to Content

Exelbine Approval Status

  • FDA approved: No
  • Brand name: Exelbine
  • Generic name: vinorelbine
  • Dosage form: Injectable Emulsion
  • Previous name: ANX-530
  • Company: Adventrx Pharmaceuticals, Inc.
  • Treatment for: Non-Small Cell Lung Cancer

Exelbine (formerly ANX-530) is a proprietary emulsion formulation of vinorelbine intended to reduce the incidence and severity of vein irritation associated with intravenous delivery of the drug. Exelbine is intended for the treatment of non-small cell lung cancer.

In August 2011, Adventrx Pharmaceuticals, Inc. announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) advising the company that the New Drug Application (NDA) for Exelbine (vinorelbine) had not been approved.

Development Status and FDA Approval Process for Exelbine

Oct  3, 2011ADVENTRX Announces Results of FDA Meeting to Discuss Exelbine NDA
Aug 10, 2011Adventrx Receives Complete Response Letter for Exelbine NDA
Jan 20, 2011Adventrx Pharmaceuticals Receives PDUFA Date for Exelbine NDA
Jan  7, 2011FDA Accepts Exelbine NDA for Filing
Nov  5, 2010Adventrx Submits Exelbine New Drug Application
May  3, 2010Adventrx to Resubmit ANX-530 NDA in the Fourth Quarter of 2010
Mar 19, 2010Adventrx Receives Brand Name Acceptance for ANX-530
Mar  2, 2010Adventrx Receives Refuse to File Letter from FDA on ANX-530 New Drug Application
Jan  6, 2010ADVENTRX Pharmaceuticals Submits ANX-530 New Drug Application

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.